Zeng Guo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Zeng Guo has a total of 61 co-authors. Here are the top co-authors by number of shared publications:
- Michael Stowasser
Endocrine Hypertension Research Centre, University of Queensland Frazer Institute, Princess Alexandra Hospital, Brisbane, Australia (M.S.).
8 shared publications Martin Wolley
From the Endocrine Hypertension Research Centre, University of Queensland Diamantina Institute, Greenslopes and Princess Alexandra Hospitals, Brisbane, Australia (Z.G., D.C., M.W., M.S.).
6 shared publicationsRichard D Gordon
Endocrine Hypertension Research Centre, University of Queensland Diamantina Institute, Greenslopes and Princess Alexandra Hospitals , Brisbane
6 shared publications- Ai-Ling Wang
Department of Cardiology, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui 230022, P.R. China
4 shared publications Ashraf H Ahmed
Endocrine Hypertension Research Centre, University of Queensland Diamantina Institute, Greenslopes and Princess Alexandra Hospitals, Brisbane, Queensland, Australia
4 shared publicationsBrett C McWhinney
Department of Chemical Pathology, Pathology Queensland, Queensland Health, Brisbane
4 shared publications
Latest Publications
- Open Access
- 3 October 2025
- Published by Springer Nature in Journal of Human Hypertension
- Vol. 39 (11) , 741-747
Comparisons of renin-angiotensin-aldosterone levels measured by chemical luminescence immunoassay and liquid chromatography-tandem mass spectrometry in hypertensive patients under different pathophysiological conditions
This study aimed to compare measurements of the renin-angiotensin-aldosterone system (RAAS) components by liquid chromatography-tandem mass spectrometry (LC-MS/MS) and chemiluminescent immunoassay (CLIA) in hypertensive patients with different gender, position and renal function. EDTA plasma from 100 hypertensive patients who completed postural test were included. Aldosterone (PAC), renin (PRC, using Autobio CLIA microparticles kit; DRC, using LIAISON Direct Renin CLIA kit), angiotensin I and II (AngI and AngII), 18-hydroxycorticosterone (18-OHB) and 18-hydroxycortisol (18-OHF) were measured. Median PACCLIA was 46.0% higher (P < 0.01) than PACLC-MS/MS. Median PACCLIA, 18-OHBLC-MS/MS and 18-OHFLC-MS/MS were higher (P < 0.01) in patients with renal dysfunction compared with patients with normal renal function, whereas median PACLC-MS/MS did not show a significant difference between the two groups. Both median PRCCLIA and DRCCLIA were higher (P < 0.01) in male patients compared with female patients. PACLC-MS/MS, PACCLIA, PRCCLIA and DRCCLIA all showed good consistency in response to an assumption of upright posture. Close (P < 0.01) correlations were observed between PACCLIA and PACLC-MS/MS, between PRCCLIA and DRCCLIA, between AngIILC-MS/MS and PRCCLIA, and between AngIILC-MS/MS and DRCCLIA. LC-MS/MS is a reliable assay for measurement of the RAAS components in hypertensive patients under different pathophysiological conditions.
- 3 October 2025
- Published by Springer Nature in Journal of Human Hypertension
- Vol. 39 (11) , 741-747
Open AccessComparisons of renin-angiotensin-aldosterone levels measured by chemical luminescence immunoassay and liquid chromatography-tandem mass spectrometry in hypertensive patients under different pathophysiological conditions
This study aimed to compare measurements of the renin-angiotensin-aldosterone system (RAAS) components by liquid chromatography-tandem mass spectrometry (LC-MS/MS) and chemiluminescent immunoassay (CLIA) in hypertensive patients with different gender, position and renal function. EDTA plasma from 100 hypertensive patients who completed postural test were included. Aldosterone (PAC), renin (PRC, using Autobio CLIA microparticles kit; DRC, using LIAISON Direct Renin CLIA kit), angiotensin I and II (AngI and AngII), 18-hydroxycorticosterone (18-OHB) and 18-hydroxycortisol (18-OHF) were measured. Median PACCLIA was 46.0% higher (P < 0.01) than PACLC-MS/MS. Median PACCLIA, 18-OHBLC-MS/MS and 18-OHFLC-MS/MS were higher (P < 0.01) in patients with renal dysfunction compared with patients with normal renal function, whereas median PACLC-MS/MS did not show a significant difference between the two groups. Both median PRCCLIA and DRCCLIA were higher (P < 0.01) in male patients compared with female patients. PACLC-MS/MS, PACCLIA, PRCCLIA and DRCCLIA all showed good consistency in response to an assumption of upright posture. Close (P < 0.01) correlations were observed between PACCLIA and PACLC-MS/MS, between PRCCLIA and DRCCLIA, between AngIILC-MS/MS and PRCCLIA, and between AngIILC-MS/MS and DRCCLIA. LC-MS/MS is a reliable assay for measurement of the RAAS components in hypertensive patients under different pathophysiological conditions.
- 1 August 2020
- Published by Wolters Kluwer Health in Hypertension
- Vol. 76 (2) , 488-496
Effects of Ramipril on the Aldosterone/Renin Ratio and the Aldosterone/Angiotensin II Ratio in Patients With Primary Aldosteronism
The aldosterone/renin ratio (ARR) is currently considered the most reliable approach for case detection of primary aldosteronism (PA). ACE (Angiotensin-converting enzyme) inhibitors are known to raise renin and lower aldosterone levels, thereby causing false-negative ARR results. Because ACE inhibitors lower angiotensin II levels, we hypothesized that the aldosterone/equilibrium angiotensin II (eqAngII) ratio (AA2R) would remain elevated in PA. Receiver operating characteristic curve analysis involving 60 patients with PA and 40 patients without PA revealed that the AA2R was not inferior to the ARR in screening for PA. When using liquid chromatography-tandem mass spectrometry to measure plasma aldosterone concentration, the predicted optimal AA2R cutoff for PA screening was 8.3 (pmol/L)/(pmol/L). We then compared the diagnostic performance of the AA2R with the ARR among 25 patients with PA administered ramipril (5 mg/day) for 2 weeks. Compared with basally, plasma levels of equilibrium angiotensin I (eqAngI) and direct renin concentration increased significantly ( P P P <0.01). The changes of plasma renin activity and plasma aldosterone concentration in the current study were not significant. On day 14, 4 patients displayed false-negative results using ARR_direct renin concentration (plasma aldosterone concentration/direct renin concentration), 3 of whom also showed false-negative ARR_plasma renin activity (plasma aldosterone concentration/plasma renin activity). On day 15, 2 patients still demonstrated false-negative ARR_plasma renin activity, one of whom also showed a false-negative ARR_direct renin concentration. No false-negative AA2R results were observed on either day 14 or 15. In conclusion, compared with ARR which can be affected by ACE inhibitors causing false-negative screening results, the AA2R seems to be superior in detecting PA among subjects receiving ACE inhibitors.
- 1 August 2020
- Published by Wolters Kluwer Health in Hypertension
- Vol. 76 (2) , 488-496
Effects of Ramipril on the Aldosterone/Renin Ratio and the Aldosterone/Angiotensin II Ratio in Patients With Primary Aldosteronism
The aldosterone/renin ratio (ARR) is currently considered the most reliable approach for case detection of primary aldosteronism (PA). ACE (Angiotensin-converting enzyme) inhibitors are known to raise renin and lower aldosterone levels, thereby causing false-negative ARR results. Because ACE inhibitors lower angiotensin II levels, we hypothesized that the aldosterone/equilibrium angiotensin II (eqAngII) ratio (AA2R) would remain elevated in PA. Receiver operating characteristic curve analysis involving 60 patients with PA and 40 patients without PA revealed that the AA2R was not inferior to the ARR in screening for PA. When using liquid chromatography-tandem mass spectrometry to measure plasma aldosterone concentration, the predicted optimal AA2R cutoff for PA screening was 8.3 (pmol/L)/(pmol/L). We then compared the diagnostic performance of the AA2R with the ARR among 25 patients with PA administered ramipril (5 mg/day) for 2 weeks. Compared with basally, plasma levels of equilibrium angiotensin I (eqAngI) and direct renin concentration increased significantly ( P P P <0.01). The changes of plasma renin activity and plasma aldosterone concentration in the current study were not significant. On day 14, 4 patients displayed false-negative results using ARR_direct renin concentration (plasma aldosterone concentration/direct renin concentration), 3 of whom also showed false-negative ARR_plasma renin activity (plasma aldosterone concentration/plasma renin activity). On day 15, 2 patients still demonstrated false-negative ARR_plasma renin activity, one of whom also showed a false-negative ARR_direct renin concentration. No false-negative AA2R results were observed on either day 14 or 15. In conclusion, compared with ARR which can be affected by ACE inhibitors causing false-negative screening results, the AA2R seems to be superior in detecting PA among subjects receiving ACE inhibitors.
- Open Access
- 9 June 2020
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 105 (9) , e3224-e3235
Biochemical, Histopathological, and Genetic Characterization of Posture-Responsive and Unresponsive APAs
Context and Objective Posture-responsive and posture-unresponsive aldosterone-producing adenomas (APAs) account for approximately 40% and 60% of APAs, respectively. Somatic gene mutations have been recently reported to exist in approximately 90% of APAs. This study was designed to characterize the biochemical, histopathologic, and genetic properties of these 2 types of APA. Methods Plasma levels of aldosterone and hybrid steroids (18-oxocortisol and 18-hydroxycortisol) were measured by liquid chromatography-tandem mass spectrometry. Immunohistochemistry for CYP11B2 (aldosterone synthase) and CYP17A1 (17α-hydroxylase) and deoxyribonucleic acid sequencing (Sanger and next-generation sequencing) were performed on APA tissue collected from 23 posture-unresponsive and 17 posture-responsive APA patients. Results Patients with posture-unresponsive APA displayed higher (P < 0.01) levels of hybrid steroids, recumbent aldosterone and cortisol, larger (P < 0.01) zona fasciculata (ZF)-like tumors with higher (P < 0.01) expression of CYP17A1 (but not of CYP11B2) than patients with posture-responsive APA (most of which were not ZF-like). Of 40 studied APAs, 37 (92.5%) were found to harbor aldosterone-driving somatic mutations (KCNJ5 = 14 [35.0%], CACNA1D = 13 [32.5%], ATP1A1 = 8 [20.0%], and ATP2B3 = 2 [5.0%]), including 5 previously unreported mutations (3 in CACNA1D and 2 in ATP1A1). Notably, 64.7% (11/17) of posture-responsive APAs carried CACNA1D mutations, whereas 56.5% (13/23) of posture-unresponsive APAs harbored KCNJ5 mutations. Conclusions The elevated production of hybrid steroids by posture-unresponsive APAs may relate to their ZF-like tumor cell composition, resulting in expression of CYP17A1 (in addition to somatic gene mutation-driven CYP11B2 expression), thereby allowing production of cortisol, which acts as the substrate for CYP11B2-generated hybrid steroids.
- 9 June 2020
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 105 (9) , e3224-e3235
Open AccessBiochemical, Histopathological, and Genetic Characterization of Posture-Responsive and Unresponsive APAs
Context and Objective Posture-responsive and posture-unresponsive aldosterone-producing adenomas (APAs) account for approximately 40% and 60% of APAs, respectively. Somatic gene mutations have been recently reported to exist in approximately 90% of APAs. This study was designed to characterize the biochemical, histopathologic, and genetic properties of these 2 types of APA. Methods Plasma levels of aldosterone and hybrid steroids (18-oxocortisol and 18-hydroxycortisol) were measured by liquid chromatography-tandem mass spectrometry. Immunohistochemistry for CYP11B2 (aldosterone synthase) and CYP17A1 (17α-hydroxylase) and deoxyribonucleic acid sequencing (Sanger and next-generation sequencing) were performed on APA tissue collected from 23 posture-unresponsive and 17 posture-responsive APA patients. Results Patients with posture-unresponsive APA displayed higher (P < 0.01) levels of hybrid steroids, recumbent aldosterone and cortisol, larger (P < 0.01) zona fasciculata (ZF)-like tumors with higher (P < 0.01) expression of CYP17A1 (but not of CYP11B2) than patients with posture-responsive APA (most of which were not ZF-like). Of 40 studied APAs, 37 (92.5%) were found to harbor aldosterone-driving somatic mutations (KCNJ5 = 14 [35.0%], CACNA1D = 13 [32.5%], ATP1A1 = 8 [20.0%], and ATP2B3 = 2 [5.0%]), including 5 previously unreported mutations (3 in CACNA1D and 2 in ATP1A1). Notably, 64.7% (11/17) of posture-responsive APAs carried CACNA1D mutations, whereas 56.5% (13/23) of posture-unresponsive APAs harbored KCNJ5 mutations. Conclusions The elevated production of hybrid steroids by posture-unresponsive APAs may relate to their ZF-like tumor cell composition, resulting in expression of CYP17A1 (in addition to somatic gene mutation-driven CYP11B2 expression), thereby allowing production of cortisol, which acts as the substrate for CYP11B2-generated hybrid steroids.
- 18 February 2020
- Published by Oxford University Press (OUP) in Clinical Chemistry
- Vol. 66 (3) , 483-492
Measurement of Equilibrium Angiotensin II in the Diagnosis of Primary Aldosteronism
Background: Many medications (including most antihypertensives) and physiological factors affect the aldosterone/renin ratio (ARR) when screening for primary aldosteronism (PA). We sought to validate a novel equilibrium angiotensin II (eqAngII) assay and compare correlations between the aldosterone/angiotensin II ratio (AA2R) and the current ARR under conditions affecting the renin-angiotensin system. Methods: Among 78 patients recruited, PA was excluded in 22 and confirmed in 56 by fludrocortisone suppression testing (FST). Peripheral levels of eqAngII, plasma renin activity (PRA) and direct renin concentration (DRC) were measured. Results: EqAngII showed good consistency with DRC and PRA independent of PA diagnosis, posture, and fludrocortisone administration. EqAngII showed close (P < 0.01) correlations with DRC (r = 0.691) and PRA (r = 0.754) during FST. DRC and PRA were below their assays’ functional sensitivity in 43.9% and 15.1%, respectively, of the total 312 samples compared with only 7.4% for eqAngII (P < 0.01). Bland-Altman analysis revealed an overestimation of PRA and DRC compared with eqAngII in a subset of samples with low renin levels. The AA2R showed not only consistent changes with the ARR but also close (P < 0.01) correlations with the ARR, whether renin was measured by DRC (r = 0.878) or PRA (r = 0.880). Conclusions: Dynamic changes of eqAngII and the AA2R show good consistency and close correlations with renin and the ARR. The eqAngII assay shows better sensitivity than DRC and PRA assays, especially at low concentrations. Whether the AA2R can reduce the impact of some factors that influence the diagnostic power of the ARR warrants further study.
- 18 February 2020
- Published by Oxford University Press (OUP) in Clinical Chemistry
- Vol. 66 (3) , 483-492
Measurement of Equilibrium Angiotensin II in the Diagnosis of Primary Aldosteronism
Background: Many medications (including most antihypertensives) and physiological factors affect the aldosterone/renin ratio (ARR) when screening for primary aldosteronism (PA). We sought to validate a novel equilibrium angiotensin II (eqAngII) assay and compare correlations between the aldosterone/angiotensin II ratio (AA2R) and the current ARR under conditions affecting the renin-angiotensin system. Methods: Among 78 patients recruited, PA was excluded in 22 and confirmed in 56 by fludrocortisone suppression testing (FST). Peripheral levels of eqAngII, plasma renin activity (PRA) and direct renin concentration (DRC) were measured. Results: EqAngII showed good consistency with DRC and PRA independent of PA diagnosis, posture, and fludrocortisone administration. EqAngII showed close (P < 0.01) correlations with DRC (r = 0.691) and PRA (r = 0.754) during FST. DRC and PRA were below their assays’ functional sensitivity in 43.9% and 15.1%, respectively, of the total 312 samples compared with only 7.4% for eqAngII (P < 0.01). Bland-Altman analysis revealed an overestimation of PRA and DRC compared with eqAngII in a subset of samples with low renin levels. The AA2R showed not only consistent changes with the ARR but also close (P < 0.01) correlations with the ARR, whether renin was measured by DRC (r = 0.878) or PRA (r = 0.880). Conclusions: Dynamic changes of eqAngII and the AA2R show good consistency and close correlations with renin and the ARR. The eqAngII assay shows better sensitivity than DRC and PRA assays, especially at low concentrations. Whether the AA2R can reduce the impact of some factors that influence the diagnostic power of the ARR warrants further study.
- 2 November 2019
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 105 (3) , e477-e483
Diagnosis of Primary Aldosteronism by Seated Saline Suppression Test—Variability Between Immunoassay and HPLC-MS/MS
Background In primary aldosteronism (PA), excessive, autonomous secretion of aldosterone is not suppressed by salt loading or fludrocortisone. For seated saline suppression testing (SSST), the recommended diagnostic cut-off 4-hour plasma aldosterone concentration (PAC) measured by HPLC-MS/MS is 162pmol/L. Most diagnostic laboratories, however, use immunoassays to measure PAC. The cut-off for SSST using immunoassay is not known. We hypothesized that the cut-off is different between the assays. Methods We analysed 80 of the 87 SSST tests that were performed during the recent study defining the HPLC-MS/MS cut-off. PA was confirmed in 65 by positive fludrocortisone suppression testing (FST) and/or lateralisation on adrenal venous sampling and excluded in 15 by negative FST. PAC was measured by a chemiluminescence immunoassay (PACIA) in the SSST samples using the DiaSorin Liaison XL analyser, and receiver operating characteristics (ROC) analysis was performed to identify the PACIA cut-off. Results ROC revealed good performance (AUC=0.893; PIA for diagnosis of PA and an optimal diagnostic cut-off of 171pmol/L, with sensitivity and specificity of 95.4% and 80.0% respectively. A higher cut-off of 217pmol/L improved specificity (86.7%) with a lower sensitivity (86.2%). PACIA measurements strongly correlated with PAC measured by HPLC-MS (r=0.94, PIA is 217pmol/L by chemiluminescence immunoassay. A grey zone exists between cut-offs of 171 and 217pmol/L, likely reflecting a lower specificity of immunoassay.
- 2 November 2019
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 105 (3) , e477-e483
Diagnosis of Primary Aldosteronism by Seated Saline Suppression Test—Variability Between Immunoassay and HPLC-MS/MS
Background In primary aldosteronism (PA), excessive, autonomous secretion of aldosterone is not suppressed by salt loading or fludrocortisone. For seated saline suppression testing (SSST), the recommended diagnostic cut-off 4-hour plasma aldosterone concentration (PAC) measured by HPLC-MS/MS is 162pmol/L. Most diagnostic laboratories, however, use immunoassays to measure PAC. The cut-off for SSST using immunoassay is not known. We hypothesized that the cut-off is different between the assays. Methods We analysed 80 of the 87 SSST tests that were performed during the recent study defining the HPLC-MS/MS cut-off. PA was confirmed in 65 by positive fludrocortisone suppression testing (FST) and/or lateralisation on adrenal venous sampling and excluded in 15 by negative FST. PAC was measured by a chemiluminescence immunoassay (PACIA) in the SSST samples using the DiaSorin Liaison XL analyser, and receiver operating characteristics (ROC) analysis was performed to identify the PACIA cut-off. Results ROC revealed good performance (AUC=0.893; PIA for diagnosis of PA and an optimal diagnostic cut-off of 171pmol/L, with sensitivity and specificity of 95.4% and 80.0% respectively. A higher cut-off of 217pmol/L improved specificity (86.7%) with a lower sensitivity (86.2%). PACIA measurements strongly correlated with PAC measured by HPLC-MS (r=0.94, PIA is 217pmol/L by chemiluminescence immunoassay. A grey zone exists between cut-offs of 171 and 217pmol/L, likely reflecting a lower specificity of immunoassay.
- 5 February 2019
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 104 (6) , 2344-2345
Response to Letter to the Editor: “Comparison of Seated With Recumbent Saline Suppression Testing for the Diagnosis of Primary Aldosteronism”
M Stowasser, Z Guo, A H Ahmed, M Wolley, R D Gordon; Response to Letter to the Editor: “Comparison of Seated with Recumbent Saline Suppression Testing for the
- 5 February 2019
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 104 (6) , 2344-2345
Response to Letter to the Editor: “Comparison of Seated With Recumbent Saline Suppression Testing for the Diagnosis of Primary Aldosteronism”
M Stowasser, Z Guo, A H Ahmed, M Wolley, R D Gordon; Response to Letter to the Editor: “Comparison of Seated with Recumbent Saline Suppression Testing for the
- Top Cited Papers
- 1 October 2018
- Published by Wolters Kluwer Health in Hypertension
- Vol. 72 (4) , 874-880
Cellular and Genetic Causes of Idiopathic Hyperaldosteronism
Primary aldosteronism affects ≈5% to 10% of hypertensive patients and has unilateral and bilateral forms. Most unilateral primary aldosteronism is caused by computed tomography-detectable aldosterone-producing adenomas, which express CYP11B2 (aldosterone synthase) and frequently harbor somatic mutations in aldosterone-regulating genes. The cause of the most common bilateral form of primary aldosteronism, idiopathic hyperaldosteronism (IHA), is believed to be diffuse hyperplasia of aldosterone-producing cells within the adrenal cortex. Herein, a multi-institution cohort of 15 IHA adrenals was examined with CYP11B2 immunohistochemistry and next-generation sequencing. CYP11B2 immunoreactivity in adrenal glomerulosa harboring non-nodular hyperplasia was only observed in 4/15 IHA adrenals suggesting that hyperplasia of CYP11B2-expressing cells may not be the major cause of IHA. However, the adrenal cortex of all IHA adrenals harbored at least 1 CYP11B2-positive aldosterone-producing cell cluster (APCC) or micro-aldosterone-producing adenomas. The number of APCCs per case (and individual APCC area) in IHA adrenals was significantly larger than in normotensive controls. Next-generation sequencing of DNA from 99 IHA APCCs demonstrated somatic mutations in genes encoding the L-type calcium voltage-gated channel subunit α 1-D ( CACNA1D , n=57; 58%) and potassium voltage-gated channel subfamily J-5 ( KCNJ5 , n=1; 1%). These data suggest that IHA may result from not only hyperplasia but also the accumulation or enlargement of computed tomography-undetectable APCC harboring somatic aldosterone-driver gene mutations. The high prevalence of mutations in the CACNA1D L-type calcium channel provides a potential actionable therapeutic target that could complement mineralocorticoid blockade and inhibit aldosterone overproduction in some IHA patients.
- 1 October 2018
- Published by Wolters Kluwer Health in Hypertension
- Vol. 72 (4) , 874-880
Top Cited PapersCellular and Genetic Causes of Idiopathic Hyperaldosteronism
Primary aldosteronism affects ≈5% to 10% of hypertensive patients and has unilateral and bilateral forms. Most unilateral primary aldosteronism is caused by computed tomography-detectable aldosterone-producing adenomas, which express CYP11B2 (aldosterone synthase) and frequently harbor somatic mutations in aldosterone-regulating genes. The cause of the most common bilateral form of primary aldosteronism, idiopathic hyperaldosteronism (IHA), is believed to be diffuse hyperplasia of aldosterone-producing cells within the adrenal cortex. Herein, a multi-institution cohort of 15 IHA adrenals was examined with CYP11B2 immunohistochemistry and next-generation sequencing. CYP11B2 immunoreactivity in adrenal glomerulosa harboring non-nodular hyperplasia was only observed in 4/15 IHA adrenals suggesting that hyperplasia of CYP11B2-expressing cells may not be the major cause of IHA. However, the adrenal cortex of all IHA adrenals harbored at least 1 CYP11B2-positive aldosterone-producing cell cluster (APCC) or micro-aldosterone-producing adenomas. The number of APCCs per case (and individual APCC area) in IHA adrenals was significantly larger than in normotensive controls. Next-generation sequencing of DNA from 99 IHA APCCs demonstrated somatic mutations in genes encoding the L-type calcium voltage-gated channel subunit α 1-D ( CACNA1D , n=57; 58%) and potassium voltage-gated channel subfamily J-5 ( KCNJ5 , n=1; 1%). These data suggest that IHA may result from not only hyperplasia but also the accumulation or enlargement of computed tomography-undetectable APCC harboring somatic aldosterone-driver gene mutations. The high prevalence of mutations in the CACNA1D L-type calcium channel provides a potential actionable therapeutic target that could complement mineralocorticoid blockade and inhibit aldosterone overproduction in some IHA patients.
- 18 September 2018
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 103 (11) , 4113-4124
Comparison of Seated With Recumbent Saline Suppression Testing for the Diagnosis of Primary Aldosteronism
Context Failure of plasma aldosterone suppression during fludrocortisone (FST) or saline suppression testing (SST) confirms primary aldosteronism (PA). Aldosterone is frequently higher upright than recumbent in PA; upright levels are used during FST. In a pilot study (24 PA patients), seated SST (SSST) was more sensitive than recumbent (RSST). Objective, Design and Patients The current validation study involved 100 patients who underwent FST, RSST and SSST, eight before and after unilateral adrenalectomy. Of the 108 FSTs, 73 confirmed and 18 excluded PA. Four patients with inconclusive FST lateralized on adrenal venous sampling making a total of 77 with PA. Results The area under the receiver-operating characteristic (ROC) curve was greater for SSST than RSST (0.96 vs. 0.80; Pvs. 94%; NS). SSST was more sensitive than RSST in detecting both unilateral (n = 28; 93 vs. 68%; Pvs. 20%; Pvs. 9 RSST and 17 FST) results were inconclusive. Conclusions SSST is highly sensitive and superior to RSST in identifying both unilateral and bilateral forms of PA, and has a low rate of false positives and inconclusive results. It therefore offers a reliable and much less complicated and expensive alternative to FST for the confirmation of PA.
- 18 September 2018
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 103 (11) , 4113-4124
Comparison of Seated With Recumbent Saline Suppression Testing for the Diagnosis of Primary Aldosteronism
Context Failure of plasma aldosterone suppression during fludrocortisone (FST) or saline suppression testing (SST) confirms primary aldosteronism (PA). Aldosterone is frequently higher upright than recumbent in PA; upright levels are used during FST. In a pilot study (24 PA patients), seated SST (SSST) was more sensitive than recumbent (RSST). Objective, Design and Patients The current validation study involved 100 patients who underwent FST, RSST and SSST, eight before and after unilateral adrenalectomy. Of the 108 FSTs, 73 confirmed and 18 excluded PA. Four patients with inconclusive FST lateralized on adrenal venous sampling making a total of 77 with PA. Results The area under the receiver-operating characteristic (ROC) curve was greater for SSST than RSST (0.96 vs. 0.80; Pvs. 94%; NS). SSST was more sensitive than RSST in detecting both unilateral (n = 28; 93 vs. 68%; Pvs. 20%; Pvs. 9 RSST and 17 FST) results were inconclusive. Conclusions SSST is highly sensitive and superior to RSST in identifying both unilateral and bilateral forms of PA, and has a low rate of false positives and inconclusive results. It therefore offers a reliable and much less complicated and expensive alternative to FST for the confirmation of PA.
- 20 August 2018
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 103 (11) , 3965-3973
Aldosterone LC-MS/MS Assay-Specific Threshold Values in Screening and Confirmatory Testing for Primary Aldosteronism
Context Current threshold values for primary aldosteronism (PA) diagnostic testing are based on measuring aldosterone (PAC) using immunoassays. Quantification of PAC by liquid chromatography-tandem mass spectrometry (LC-MS/MS) yields lower values. Objective To compare aldosterone measurement by radioimmunoassay (RIA) with LC-MS/MS and evaluate performances of proposed LC-MS/MS-specific cut-offs for PA screening and confirmatory testing. Patients and Intervention Forty-one patients underwent aldosterone/renin ratio (ARR) testing to screen for, and fludrocortisone suppression testing (FST) to confirm or exclude, PA. Main Outcome Measures Aldosterone was measured by both RIA and LC-MS/MS while direct renin concentration (DRC) was measured by chemiluminescent immunoassay. Results Median serum PACLC-MS/MS was 27.8% lower (pRIA in 164 pairs of FST samples. A positive correlation (Spearman coefficient 0.894, pr coefficient 0.861, ppRIA cut-off of 165 pmol/L and the proposed PACLC-MS/MS cut-off of 133 pmol/L. Among 37 patients with consistent FST results, no differences were observed in sensitivity (89.7% vs 93.1%) or specificity (87.5% vs 87.5%) for PA screening between the current ARR cut-off of 70 pmol/mU (PACRIA/DRC) and the proposed cut-off of 55 pmol/mU (PACLC-MS/MS/DRC). Conclusions Adjustment of the current cut-offs for PA diagnostic testing is necessary if PAC is measured by LC-MS/MS. Preliminary results of this study suggest that our proposed LC-MS/MS cut-offs for ARR and FST perform as well as current RIA cut-offs.
- 20 August 2018
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 103 (11) , 3965-3973
Aldosterone LC-MS/MS Assay-Specific Threshold Values in Screening and Confirmatory Testing for Primary Aldosteronism
Context Current threshold values for primary aldosteronism (PA) diagnostic testing are based on measuring aldosterone (PAC) using immunoassays. Quantification of PAC by liquid chromatography-tandem mass spectrometry (LC-MS/MS) yields lower values. Objective To compare aldosterone measurement by radioimmunoassay (RIA) with LC-MS/MS and evaluate performances of proposed LC-MS/MS-specific cut-offs for PA screening and confirmatory testing. Patients and Intervention Forty-one patients underwent aldosterone/renin ratio (ARR) testing to screen for, and fludrocortisone suppression testing (FST) to confirm or exclude, PA. Main Outcome Measures Aldosterone was measured by both RIA and LC-MS/MS while direct renin concentration (DRC) was measured by chemiluminescent immunoassay. Results Median serum PACLC-MS/MS was 27.8% lower (pRIA in 164 pairs of FST samples. A positive correlation (Spearman coefficient 0.894, pr coefficient 0.861, ppRIA cut-off of 165 pmol/L and the proposed PACLC-MS/MS cut-off of 133 pmol/L. Among 37 patients with consistent FST results, no differences were observed in sensitivity (89.7% vs 93.1%) or specificity (87.5% vs 87.5%) for PA screening between the current ARR cut-off of 70 pmol/mU (PACRIA/DRC) and the proposed cut-off of 55 pmol/mU (PACLC-MS/MS/DRC). Conclusions Adjustment of the current cut-offs for PA diagnostic testing is necessary if PAC is measured by LC-MS/MS. Preliminary results of this study suggest that our proposed LC-MS/MS cut-offs for ARR and FST perform as well as current RIA cut-offs.